Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
This is a randomized and double-blinded within study group, placebo-controlled trial to
evaluate the safety, tolerability and immunological profile of INO-4500 administered by
intradermal (ID) injection followed by electroporation using the CELLECTRA® 2000 device in
healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Inovio Pharmaceuticals
Collaborators:
Coalition for Epidemic Preparedness Innovations Coalition for Epidemic Preparedness Innovations (CEPI)